C.S. Muralidharan Joins Emcure Pharmaceuticals As Independent Director

Emcure Pharmaceuticals has appointed C.S. Muralidharan as Non-Executive Independent Director (Additional Director) with effect from April 1, 2026, subject to the approval of the shareholders.

During his career, Muralidharan has worked with organisations such as Indian Oil Corporation Ltd., Ranbaxy Laboratories, Lupin Ltd., Matrix Laboratories, and Watson Pharmaceuticals. He also served as Group Chief Financial Officer (GCFO) at Sun Pharmaceutical Industries. He has more than four decades of experience in the hydrocarbon and pharmaceutical sectors. His work has included roles linked to strategy, mergers and acquisitions (M&A), enterprise risk management, and environmental, social, & governance (ESG) initiatives. Muralidharan is a Cost and Management Accountant and completed the Executive Programme in General Management from the University of Chicago Booth School of Business.

a

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: